BioSpace News Archive

Aditxt, Inc. announced that it will effect a 1-for-40 reverse split of its common stock effective as of 9:30 a.m. Eastern Time on August 18, 2023.

ALS Finding a Cure® (ALSFAC) and The ALS Association announced today seven new grants worth a total of $2 million to support the development of early diagnostics for ALS.

Health Alliance Plan (HAP), a Michigan-based nonprofit health plan, and CareSource, an Ohio-based nonprofit managed care health plan, received regulatory approval to move forward with their joint venture after a comprehensive review by state and federal regulatory agencies.

TFF Pharmaceuticals, Inc. announced the closing of its $5.7 million underwritten public offering of 22,880,400 shares of its common stock, including 2,984,400 shares of its common stock issued pursuant to the full exercise by the underwriter of its over-allotment option.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Day at the newly constructed Dr. Walter Gilbert Innovation Center in South San Francisco on September 19, 2023.

As previously announced, on July 16, 2023, MediPacific Sub, Inc. and MediPacific, Inc., affiliates of Foresite Capital, entered into a definitive agreement and plan of merger with Pardes Biosciences, Inc..

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases and cancer, today announced that the Company has achieved an undisclosed milestone payment from Boston Pharmaceuticals.

NextPoint Therapeutics announced today that the first patient has been dosed with NPX267 in a Phase 1 first-in-human clinical trial for the treatment of patients with solid tumors known to express HHLA2, a tumor antigen strongly upregulated in many human tumors independently of PD-L1.

NANO-X IMAGING LTD today announced results for the second quarter ended June 30, 2023 and provided a business update.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host a hybrid Investor & Analyst Event on Tuesday, September 19 from 9:00 a.m. to 1:00 p.m. Eastern Time in New York.